ABSTRACT
To identify the associations between different genotypes of TLR9 -1486T/C (rs187084) with gastric cancer patients and reveal their relation to Helicobacter pylori virulence genes (cagA, sodB, hsp60 and vacA). Patients with gastric cancer were recruited to our study, diagnosed both endoscopically and histopathologically. H. pylori were isolated from gastric samples by culture and PCR amplification of the glmM gene. Virulence genes cagA, sodB, hsp60, and vacA were detected by multiplex PCR. Blood samples were used for genotyping of TLR9 -1486T/C (rs187084) by PCR-RFLP. Out of 132 patients with gastric cancer, 106 (80.3%) were positive for H. pylori. A similar number of healthy participants was recruited as controls. The prevalence of cagA, sodB, hsp60, and vacA genes among H. pylori was 90.6%, 70.8%, 83.0%, and 95.3%, respectively. The vacA gene alleles had a prevalence of 95.3% for vacAs1/s2, 52.8% for vacAm1, and 42.5% for vacAm2. The CC genotype of TLR9 -1486T/C had a significantly higher frequency in gastric cancer patients when compared to healthy participants (p = 0.045). Furthermore, the CC genotype demonstrated a significant association with H. pylori strains carrying sodB, hsp60, and vacAm1 virulence genes (p = 0.021, p = 0.049, and p = 0.048 respectively). Patients with CC genotype of TLR9 -1486T/C (rs187084) might be at higher risk for the development of gastric cancer, and its co-existence with H. pylori strains carrying sodB, hsp60, or vacAm1 virulence genes might have a synergistic effect in the development of gastric cancer. Further studies on a wider scale are recommended.
Subject(s)
Helicobacter Infections , Helicobacter pylori , Stomach Neoplasms , Antigens, Bacterial/genetics , Bacterial Proteins/genetics , Helicobacter pylori/genetics , Humans , Polymorphism, Genetic , Superoxide Dismutase , Toll-Like Receptor 9/genetics , Virulence/geneticsABSTRACT
Introduction: Chlorhexidine is an antiseptic agent which is extensively used to prevent nosocomial infections; however, this could result in reduction of its susceptibility. The aim of this work was to determine chlorhexidine susceptibility among Staphylococcus aureus isolates and to detect qacA/B and smr antiseptic resistance genes among these isolates. Furthermore, we aimed to identify possible risk factors for the reduction of chlorhexidine susceptibility among S. aureus isolates. Methods: Various clinical samples were collected from patients with evidence of S. aureus infection. Antimicrobial susceptibilities of identified S. aureus isolates were determined by disk diffusion method. Resistance to methicillin was identified by cefoxitin disk diffusion test besides mecA gene detection by PCR. Chlorhexidine minimum inhibitory concentration (MIC) values were measured by broth microdilution method while qacA/B and smr resistance genes were detected by multiplex PCR. Results: A total percentage of 25.9% of S. aureus isolates showed reduced susceptibility to chlorhexidine. Methicillin resistant S. aureus (MRSA) had a reported percentage of 39.5%, which was significantly higher than the 11.3% reported for methicillin susceptible S. aureus (MSSA), p<0.001. S. aureus isolates were found to harbor qacA/B and smr genes at 23.2% and 7.7% respectively. Risk factors for reduced susceptibility to chlorhexidine included; ICU setting (OR=2.02, 95%CI: 0.3-1.6), prolonged ICU stay (OR=1.7, 95%CI: 0.4-1.1), presence of central vascular catheter (OR=2.3, 95%CI: 0.2-1.9), mechanical ventilation (OR=1.88, 95%CI: 0.4-1.7) and acquisition of qacA/B (OR=15.7, 95%CI: 3.4-12.1) or smr gene (OR=15.7, 95%CI: 3.4-12.1). Conclusions: Our work highlighted the current challenge of antiseptic resistance in our locality. The frequencies of qacA/B and smr genes were significantly higher among MRSA than MSSA isolates. About two thirds of chlorhexidine tolerant isolates displayed an MDR profile. To maintain chlorhexidine efficiency, biocidal stewardship program and ongoing surveillance are essential.
ABSTRACT
Introduction. The resistance to quinolone reported in uropathogenic Escherichia coli (UPEC) is commonly caused by mutations in the target site encoding genes such as the gyrA gene. Bacterial plasmids carrying resistance genes such as qnr genes can also transfer resistance. Biofilms produced by UPEC can further aid the development of resistant urinary tract infections (UTIs).Hypothesis. Biofilm production is associated with higher prevalence of quinolones resistance genetic determinants.Aim. To detect the prevalence of qnr genes and gyrA gene mutation among quinolone-resistant UPEC and to investigate the relation between these genetic resistance determinants and biofilm production.Methodology. Catheterized urine samples were collected from 420 patients with evidence of UTIs and processed using standard techniques. Isolated UPEC were screened for quinolone resistance using an antimicrobial susceptibility test. Biofilm production among quinolone-resistant isolates was detected using the tissue culture plate method. All quinolone-resistant isolates were screened for qnr genes (qnrA, qnrB and qnrS) by multiplex PCR and for gyrA gene mutation by PCR-RFLP.Results. Two hundred and sixty-four UPEC isolates were detected from 420 processed urine samples. Out of the identified 264 UPEC, 123 (46.6â%) isolates were found to be quinolone-resistant, showing resistance to 1 or more of the tested quinolones. Of the 123 quinolone-resistant UPEC detected, 71(57.7â%) were biofilm producers. The qnr genes were detected among 62.6â% of the quinolone-resistant UPEC, with an estimated prevalence of 22.8, 32.5 and 37.4â% for qnrA, qnrB and qnrS genes, respectively. Additionally, the gyrA gene mutation was identified among 53.7â% of the quinolone-resistant isolates. We reported a significant association between biofilm production and the presence of qnrA, qnrB and qnrS genes. Furthermore, the gyrA gene mutation was significantly associated with biofilm-producing isolates. The coexistence of qnr genes, gyrA gene mutation and biofilm production was demonstrated in almost 40â% of the quinolone-resistant isolates.Conclusions. A significantly higher prevalence of qnr genes (qnrA, qnrB and qnrS) as well as the gyrA gene mutation was found among biofilm-forming UPEC. The reported coexistence of these different resistance mechanisms could aggravate quinolone resistance. Therefore, monitoring of resistance mechanisms and a proper stewardship programme are necessary.
Subject(s)
Biofilms/growth & development , Drug Resistance, Bacterial/genetics , Escherichia coli Infections/microbiology , Escherichia coli Proteins/genetics , Urinary Tract Infections/microbiology , Uropathogenic Escherichia coli , Humans , Uropathogenic Escherichia coli/genetics , Uropathogenic Escherichia coli/growth & developmentABSTRACT
OBJETIVOS: El objetivo del estudio fue evaluar si el uso de heliox (79:21) administrado vía cánula nasal de bajo flujo mejora el trabajo respiratorio en lactantes con bronquiolitis aguda causada por virus respiratorio sincitial. MÉTODOS: Se realizó un estudio prospectivo aleatorizado controlado. Todos los pacientes que cumplieron los criterios de inclusión se asignaron al azar a tratamiento con heliox (79:21) o con aire, administrados mediante cánula nasal a razón de 2 L/min durante un período ininterrumpido de 24 h. Se realizaron medidas basales, a las 2 h de iniciar el tratamiento y al completarse las 24 h. RESULTADOS: Se incluyeron 104 pacientes en el estudio. No se observaron diferencias significativas en la puntuación de la M-WCAS entre los dos grupos a las 2 h (4,3 vs. 4,1; p = 0,78) o al completarse las 24 h (4,2 vs. 4,3; p = 0,89). No hubo diferencias en las proporciones de participantes que progresaron a ventilación mecánica, CPAP-n u oxigenoterapia administrada mediante cánula nasal (RR: 1,0, 0,86 y 0,89; p = 1,0, 0,77 y 0,73). No hubo una reducción significativa en la duración de tratamiento, de 2,42 días en el grupo tratado con heliox y de 2,79 días en el grupo tratado con aire (p = 0,65). Tampoco hubo diferencias significativas entre los dos grupos bajo estudio en la saturación de oxígeno, PaO2 o PaCO2 a las 2 y a las 24 h de tratamiento. CONCLUSIONES: Nuestros datos no mostraron ningún efecto beneficioso del heliox a una concentración de 79:21 administrado vía cánula nasal de bajo flujo en cuanto a la mejoría de la dificultad respiratoria en lactantes con bronquiolitis aguda por VRS
OBJECTIVES: The aim of our study is to evaluate whether the use of heliox (79:21) delivered through a low flow nasal cannula would improve respiratory distress in infants with acute bronchiolitis caused by respiratory syncytial virus. METHODS: We have conducted a prospective randomized controlled study. All patients fulfilled inclusion criteria were randomized to either heliox (79:21) or air via NC at 2 L/min for a continuous 24 hours. Measurements were taken at baseline, after 2hours and at the end of the 24hours. RESULTS: We have included 104 patients into our study. The MCA-S did not show any significant difference between the two groups after 2hours 4.3 vs. 4.1 (P =.78), or at 24hours after 4.2 vs. 4.3 (P =.89). No difference was found in the proportion of participants progressed to MV, n-CPAP or oxygen via nasal cannula (RR 1.0, 0.86 and 0.89) (P= 1.0, .77 and .73). There was no notable reduction in length of treatment in Heliox group 2.42 days vs. 2.79 days in air group P =.65. The in oxygen saturation, PaO2, and PaCO2 did not to have any statistical difference between the two studied groups after 2 hours and 24 hours of treatment. CONCLUSION: Our data showed absence of any beneficial effect of heliox in a concentration (79:21) delivered through low flow nasal cannula in terms of respiratory distress improvement in infants with RSV acute bronchiolitis
Subject(s)
Humans , Infant, Newborn , Infant , Child, Preschool , Respiratory Distress Syndrome, Newborn/therapy , Helium/administration & dosage , Bronchiolitis/complications , Cannula , Bronchiolitis/therapy , Respiratory Syncytial Viruses , Prospective Studies , Respiration, ArtificialABSTRACT
OBJECTIVES: The aim of our study is to evaluate whether the use of heliox (79:21) delivered through a low flow nasal cannula would improve respiratory distress in infants with acute bronchiolitis caused by respiratory syncytial virus. METHODS: We have conducted a prospective randomized controlled study. All patients fulfilled inclusion criteria were randomized to either heliox (79:21) or air via NC at 2 L/min for a continuous 24hours. Measurements were taken at baseline, after 2hours and at the end of the 24hours. RESULTS: We have included 104 patients into our study. The MCA-S did not show any significant difference between the two groups after 2hours 4.3 vs. 4.1 (P =.78), or at 24hours after 4.2 vs. 4.3 (P =.89). No difference was found in the proportion of participants progressed to MV, n-CPAP or oxygen via nasal cannula (RR 1.0, 0.86 and 0.89) (P= 1.0, .77 and .73). There was no notable reduction in length of treatment in Heliox group 2.42 days vs. 2.79 days in air group P =.65. The in oxygen saturation, PaO2, and PaCO2 did not to have any statistical difference between the two studied groups after 2hours and 24hours of treatment. CONCLUSION: Our data showed absence of any beneficial effect of heliox in a concentration (79:21) delivered through low flow nasal cannula in terms of respiratory distress improvement in infants with RSV acute bronchiolitis.
Subject(s)
Bronchiolitis/virology , Helium/administration & dosage , Oxygen/administration & dosage , Respiration Disorders/drug therapy , Respiration Disorders/virology , Respiratory Syncytial Virus Infections/complications , Acute Disease , Cannula , Humans , Infant , Prospective Studies , Respiratory Therapy/instrumentation , Respiratory Therapy/methods , Treatment OutcomeABSTRACT
OBJECTIVES: Acinetobacter baumannii is a causative pathogen of various healthcare-associated infections (HAIs) and is particularly prevalent in high-risk hospital settings. This study aimed to determine risk factors associated with HAIs caused by carbapenem-resistant A. baumannii (CRAB) in a neonatal intensive care unit (NICU). METHODS: This prospective study was performed between January 2013 and June 2014 among NICU patients at the Mansoura University Children's Hospital, Mansoura, Egypt. Neonates who developed HAIs due to CRAB were assigned to a case group, while those infected with carbapenem-sensitive A. baumannii (CSAB) were assigned to a control group. RESULTS: Among the 124 neonates who developed A. baumannii-caused HAIs during the study period, 91 (73.4%) were caused by CRAB and 33 (26.6%) were caused by CSAB. Prematurity, premature rupture of the membranes (PROM), a previous stay in another hospital, prolonged NICU stay, the presence of invasive devices, previous exposure to carbapenems or aminoglycosides and prolonged antibiotic therapy before infection were significantly associated with CRAB-caused HAIs. A multivariate logistic regression analysis identified prematurity (adjusted odds ratio [aOR] = 25.3; P <0.01), mechanical ventilation (aOR = 18.9; P <0.01) and the previous use of carbapenems (aOR = 124.7; P <0.01) or aminoglycosides (aOR = 22.6; P = 0.04) to be independent risk factors for CRAB infections. CONCLUSION: Various risk factors were significantly associated with CRAB-caused HAIs among the studied NICU patients.
Subject(s)
Acinetobacter Infections/drug therapy , Cross Infection/drug therapy , Cross Infection/etiology , Drug Resistance, Bacterial , Acinetobacter baumannii/pathogenicity , Carbapenems/therapeutic use , Egypt , Female , Humans , Infant, Newborn , Intensive Care Units, Neonatal/organization & administration , Male , Microbial Sensitivity Tests/methods , Odds Ratio , Prospective Studies , Risk FactorsABSTRACT
BACKGROUND: The aim of this study was to investigate whether presepsin level in umbilical cord blood can be used as a predictor of early onset neonatal sepsis (EONS) in preterm labor with premature rupture of membranes (PROM), allowing rational use of antibiotics. METHODS: All preterm infants between 24 + 0 and 36 + 6 weeks of gestation born to pregnant women with PROM were enrolled in the study. Blood samples were obtained from clamped umbilical cords after delivery of the neonate and prior to the delivery of the placenta for C-reactive protein and presepsin measurement. A diagnosis or suspicion of EONS was based on clinical symptoms or laboratory results in the absence of positive blood culture. RESULTS: A total of 288 women were included in the study and delivered at 31 + 4 weeks (range, 25-36 + 5 weeks). Microbial invasion of the amniotic cavity was identified in 62 women (81.6%) with EONS and in 31 (14.6%) without (P = 0.004). The prevalence of EONS was 26.4% (76/288). Median umbilical cord presepsin was significantly higher in neonates with EONS than in those without: 2,231 pg/mL (range, 1,442-3,988 pg/mL) versus 275 pg/mL (range, 116-326 pg/mL; P < 0.000). On logistic regression analysis the only independent predictor of EONS was umbilical cord blood presepsin (OR, 12.6; 95% CI: 2.5-28.1, P = 0.000). CONCLUSIONS: Umbilical cord blood presepsin is a predictor for EONS in preterm infants with PROM and may help to reduce the unnecessary use of antibiotics.
Subject(s)
Fetal Blood/metabolism , Fetal Membranes, Premature Rupture/blood , Lipopolysaccharide Receptors/blood , Neonatal Sepsis/blood , Peptide Fragments/blood , Biomarkers/blood , Female , Humans , Infant, Newborn , Infant, Premature/blood , Neonatal Sepsis/epidemiology , Pregnancy , Prospective Studies , Umbilical CordABSTRACT
Abstract Objective: The objective of this study is to evaluate the hypothesis that use of heliox would result in improvement of gas exchange when used with high flow nasal cannula in infants with RSV acute bronchiolitis. Methods: All patients that met the inclusion criteria were randomized to either heliox (70:30) or air-oxygen mixture 30% via high flow nasal cannula at 8 L/min for a continuous 24 h. Measurements were taken at baseline, after 2 h, and at the end of the 24 h. Results: This prospective study included 48 patients. After 2 h of treatment with heliox, the oxygen saturation and PaO2 significantly improved when compared with the air-oxygen group, 98.3% vs. 92.9%, 62.0 mmHg vs. 43.6 mmHg (p = 0.04 and 0.01), respectively. Furthermore, PaO2/FiO2 ratio was significantly higher in the heliox group when compared with the air-oxygen group, 206.7 vs. 145.3. Nevertheless, CO2 showed better elimination when heliox was used, without significance. MWCA score dropped significantly in the heliox group, 2.2 points vs. 4.0 points in air-oxygen (p = 0.04), 2 h after starting the therapy. Conclusion: Transient improvement of oxygenation in infants with RSV acute bronchiolitis during the initial phase of the therapy is associated with heliox when provided with HFNC, may provide a precious time for other therapeutic agents to work or for the disease to resolve naturally, avoiding other aggressive interventions.
Resumo Objetivo: Avaliar a hipótese de que o uso da mistura heliox resultaria em melhoria da troca gasosa quando usado com cânula nasal de alto fluxo em crianças com bronquiolite aguda por VSR. Métodos: Todos os pacientes que atenderam aos critérios de inclusão foram randomizados para receber a mistura heliox (70:30) ou a mistura ar/oxigênio a 30% por meio da cânula nasal de alto fluxo a 8 L/min por 24 horas contínuas. As medições foram feitas no início, depois de duas horas e ao fim de 24 horas. Resultados: Fizemos um estudo prospectivo em que foram incluídos 48 pacientes. Após duas horas de tratamento com a mistura heliox, a saturação de oxigênio e a PaO2 apresentaram melhoria significativa em comparação com o grupo da mistura ar/oxigênio: 98,3% em comparação com 92,9%, 62,0 mmHg em comparação com 43,6 mmHg (p = 0,04 e 0,01), respectivamente. Além disso, a relação PaO2/FiO2 era significativamente mais alta no grupo da mistura heliox do que no grupo da mistura ar/oxigênio, 2.067 em comparação com 1.453. Contudo, o CO2 apresentou melhor eliminação quando a mistura heliox foi usada, sem relevância. O Escore MWCA caiu significativamente no grupo da mistura heliox, 2,2 pontos em comparação com 4,0 pontos da mistura ar/oxigênio (p = 0,04) duas horas após o início da terapia. Conclusão: A breve melhoria da oxigenação em crianças com bronquiolite aguda por VSR na fase inicial da terapia está associada à mistura heliox quando administrada pela CNAF e poderá fornecer um tempo precioso para outros agentes terapêuticos funcionarem ou para a própria doença se curar naturalmente e evitar outras intervenções agressivas.
Subject(s)
Humans , Male , Female , Infant, Newborn , Infant , Child, Preschool , Oxygen/administration & dosage , Oxygen Inhalation Therapy/methods , Bronchiolitis, Viral/therapy , Respiratory Syncytial Virus Infections/therapy , Cannula , Helium/administration & dosage , Bronchiolitis, Viral/virology , Acute Disease , Prospective Studies , Treatment OutcomeABSTRACT
OBJECTIVE: The objective of this study is to evaluate the hypothesis that use of heliox would result in improvement of gas exchange when used with high flow nasal cannula in infants with RSV acute bronchiolitis. METHODS: All patients that met the inclusion criteria were randomized to either heliox (70:30) or air-oxygen mixture 30% via high flow nasal cannula at 8L/min for a continuous 24h. Measurements were taken at baseline, after 2h, and at the end of the 24h. RESULTS: This prospective study included 48 patients. After 2h of treatment with heliox, the oxygen saturation and PaO2 significantly improved when compared with the air-oxygen group, 98.3% vs. 92.9%, 62.0mmHg vs. 43.6mmHg (p=0.04 and 0.01), respectively. Furthermore, PaO2/FiO2 ratio was significantly higher in the heliox group when compared with the air-oxygen group, 206.7 vs. 145.3. Nevertheless, CO2 showed better elimination when heliox was used, without significance. MWCA score dropped significantly in the heliox group, 2.2 points vs. 4.0 points in air-oxygen (p=0.04), 2h after starting the therapy. CONCLUSION: Transient improvement of oxygenation in infants with RSV acute bronchiolitis during the initial phase of the therapy is associated with heliox when provided with HFNC, may provide a precious time for other therapeutic agents to work or for the disease to resolve naturally, avoiding other aggressive interventions.
Subject(s)
Bronchiolitis, Viral/therapy , Cannula , Helium/administration & dosage , Oxygen Inhalation Therapy/methods , Oxygen/administration & dosage , Respiratory Syncytial Virus Infections/therapy , Acute Disease , Bronchiolitis, Viral/virology , Child, Preschool , Female , Humans , Infant , Infant, Newborn , Male , Prospective Studies , Treatment OutcomeABSTRACT
Tea phenolic acids and catechins containing gallic acid moieties are most abundant in green tea, and various medical benefits have been proposed from their consumption. In the following, the cytotoxicities of these major tea phenolics toward isolated rat hepatocytes have been ranked and the mechanisms of cytotoxicity evaluated. The order of cytotoxic effectiveness found was epigallocatechin-3-gallate>propyl gallate>epicatechin-3-gallate>gallic acid, epigallocatechin>epicatechin. Using gallic acid as a model tea phenolic and comparing it with the tea catechins and gallic acid-derivative food supplements, the major cytotoxic mechanism found with hepatocytes was mitochondrial membrane potential collapse and ROS formation. Epigallocatechin-3-gallate was also the most effective at collapsing the mitochondrial membrane potential and inducing ROS formation. Liver injury was also observed in vivo when these tea phenolics were administered ip to mice, as plasma alanine aminotransferase levels were significantly increased. In contrast, GSH conjugation, methylation, metabolism by NAD(P)H:quinone oxidoreductase 1, and formation of an iron complex were important in detoxifying the gallic acid. In addition, for the first time, the GSH conjugates of gallic acid and epigallocatechin-3-gallate have been identified using mass spectrometry. These results add insight into the cytotoxic and cytoprotective mechanisms of the simple tea phenolic acids and the more complex tea catechins.
